Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Next Previous
Trial Profile

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonvoguran ziclumeran (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Intellia Therapeutics

Most Recent Events

  • 03 Mar 2026 According to an Intellia Therapeutics media release, the company plans to preset results of this trial at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI).
  • 09 Nov 2025 According to an Intellia Therapeutics media release, company presented positive clinical data from a pooled analysis of all patients who received a 50 milligram (mg) dose of lonvo-z in the company's ongoing Phase 1/2 clinical trial in patients with hereditary angioedema (HAE). at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida.
  • 07 Nov 2025 According to an Intellia Therapeutics media release, On November 8, 2025 at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting (ACAAI), longer-term clinical data will be presented in an oral session from all patients who received a 50 mg dose of lonvo-z in company's ongoing Phase 1/2 clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top